Melody Cobleigh to Randomized Controlled Trials as Topic
This is a "connection" page, showing publications Melody Cobleigh has written about Randomized Controlled Trials as Topic.
Connection Strength
0.132
-
Managing menopausal problems. Cancer Treat Res. 2000; 103:1-23.
Score: 0.038
-
Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer. Ann Oncol. 2016 06; 27(6):1029-1034.
Score: 0.030
-
ACR appropriateness criteria on postmastectomy radiotherapy expert panel on radiation oncology-breast. Int J Radiat Oncol Biol Phys. 2009 Mar 15; 73(4):997-1002.
Score: 0.018
-
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol. 2005 Jan 20; 23(3):619-29.
Score: 0.013
-
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002. J Clin Oncol. 2002 Aug 01; 20(15):3317-27.
Score: 0.012
-
First-line, single-agent Herceptin(trastuzumab) in metastatic breast cancer: a preliminary report. Eur J Cancer. 2001 Jan; 37 Suppl 1:S25-9.
Score: 0.010
-
First-line Herceptin monotherapy in metastatic breast cancer. Oncology. 2001; 61 Suppl 2:37-42.
Score: 0.010